Tanios Bekaii-Saab, MD: Experience With Patients on Bevacizumab Plus Chemotherapy
What is your experience with patients who receive bevacizumab plus a CT regimen? What types of issues/side effects do they report with treatment?
Bevacizumab is relatively safe to administer with chemotherapy. It doesn't seem to exacerbate or worsen the chemotherapy toxicities. It has its toxicities, like we said with hypertension, proteinuria, arterial thromboembolic events which are rare if you choose the right patients, and issues with bowel perforation which is also a rare event. Overall, adding bevacizumab to chemotherapy seems to be fairly safe as long as you select the right patients and you are careful about stopping the bevacizumab 4 to 6 weeks prior to surgical resection, and then starting again 4 to 6 weeks after surgery.
Unresectable Colon Cancer: Case 1
68-year-old man was diagnosed with advanced, unresectable colon cancer has just started treatment with FOLFIRI plus bevacizumab.
Phase 3 Trials of Botensilimab/Balstilimab Move Forward, Despite FDA's Approval Setback
July 18th 2024Agenus was advised by the FDA against filing for accelerated approval of botensilimab plus balstilimab for relapsed/refractory microsatellite stable metastatic colorectal cancer without liver metastases.
Read More
